MedTrace Logo

A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT05057494 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 607

Last updated 2026-05-19

No results posted yet for this study

Summary

A study of acalabrutinib plus venetoclax (AV) versus venetoclax plus obinutuzumab (VO) in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.

Conditions

  • Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Interventions

DRUG

Acalabrutinib

Dose formulation: Capsule or Tablet

DRUG

Venetoclax

Dose formulation: Tablet

DRUG

Obinutuzumab

Dose formulation: Injection

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-12
Primary Completion
2027-07-15
Completion
2029-04-10
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Czechia
  • France
  • Hungary
  • Poland
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05057494 on ClinicalTrials.gov